Abstract
G protein-coupled receptors represent one of the largest families of drug targets. Time and cost may be saved if GPCR modulators are assessed in terms of signaling pathway selectivity, species selectivity, and selectivity against closely-related family members early in the drug discovery process, perhaps even at the stage of high-throughput screening. Examples are given of how these kinds of selectivity have been addressed during screening.
Keywords: β-Arrestin, desensitization, G protein-coupled receptor, selectivity, G protein, high throughput screening, receptor subtype, species, Arrestin, 2-adrenergic receptor, (hydroxyphenylorciprenaline), GPCR signaling, MAPKs, angiotensin II receptor type 1, parathy-roid hormone receptor, protease activated receptor, vasopressin 2 receptor, herkinorin, Ligand Pharmaceutical's Encoded Combinatorial Librar-ies on Polymeric Support, bradykinin receptor 1, melano-cortin (MC)-4 receptor (MC4R)
Current Pharmaceutical Biotechnology
Title: Pathway-Specific, Species, and Sub-Type Counterscreening for Better GPCR Hits in High Throughput Screening
Volume: 11 Issue: 7
Author(s): Robert Swanson and James R. Beasley
Affiliation:
Keywords: β-Arrestin, desensitization, G protein-coupled receptor, selectivity, G protein, high throughput screening, receptor subtype, species, Arrestin, 2-adrenergic receptor, (hydroxyphenylorciprenaline), GPCR signaling, MAPKs, angiotensin II receptor type 1, parathy-roid hormone receptor, protease activated receptor, vasopressin 2 receptor, herkinorin, Ligand Pharmaceutical's Encoded Combinatorial Librar-ies on Polymeric Support, bradykinin receptor 1, melano-cortin (MC)-4 receptor (MC4R)
Abstract: G protein-coupled receptors represent one of the largest families of drug targets. Time and cost may be saved if GPCR modulators are assessed in terms of signaling pathway selectivity, species selectivity, and selectivity against closely-related family members early in the drug discovery process, perhaps even at the stage of high-throughput screening. Examples are given of how these kinds of selectivity have been addressed during screening.
Export Options
About this article
Cite this article as:
Swanson Robert and R. Beasley James, Pathway-Specific, Species, and Sub-Type Counterscreening for Better GPCR Hits in High Throughput Screening, Current Pharmaceutical Biotechnology 2010; 11 (7) . https://dx.doi.org/10.2174/138920110792927775
DOI https://dx.doi.org/10.2174/138920110792927775 |
Print ISSN 1389-2010 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4316 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Chaperone Therapy: New Molecular Therapy for Protein Misfolding Diseases with Brain Dysfunction
Current Bioinformatics Atrial Remodeling and Novel Pharmacological Strategies for Antiarrhythmic Therapy in Atrial Fibrillation
Current Medicinal Chemistry Nutritional Status and Lipid Profile in HIV-Infected Adults
Endocrine, Metabolic & Immune Disorders - Drug Targets Therapy Of Cardiac Arrhythmias In Children: An Emerging Role Of Electroanatomical Mapping Systems
Current Vascular Pharmacology Atrial and Brain Natriuretic Peptides- Benefits and Limits of their use in Cardiovascular Diseases
Current Cardiology Reviews Current Status and Future Prospects of C1 Domain Ligands as Drug Candidates
Current Topics in Medicinal Chemistry The Impact of Smoking on Cardiovascular Outcomes and Comorbidities in Statin-treated Patients with Coronary Artery Disease: A Post hoc Analysis of the GREACE Study
Current Vascular Pharmacology Meet Our Editorial Board Member:
Current Vascular Pharmacology Cardiovascular Effects of Modulators of Soluble Guanylyl Cyclase Activity
Cardiovascular & Hematological Agents in Medicinal Chemistry Telomerase Modulation in Therapeutic Approach
Current Pharmaceutical Design Hypoxia-Inducible Factor-1 in Arterial Disease: A Putative Therapeutic Target
Current Vascular Pharmacology Peri-Procedural Care of Renal Nerve Ablation Candidates
Current Clinical Pharmacology Design and Synthesis of an Aniline Derivative with Biological Activity on Heart Failure
Combinatorial Chemistry & High Throughput Screening Mesenchymal Stem Cells in Veterinary Regenerative Therapy: Basic Physiology and Clinical Applications
Current Stem Cell Research & Therapy FK506-Binding Proteins and Their Diverse Functions
Current Molecular Pharmacology Genetic Basis, Nutritional Challenges and Adaptive Responses in the Prenatal Origin of Obesity and Type-2 Diabetes
Current Diabetes Reviews Long Non-Coding RNA GAS5 in Age-Related Diseases
Current Medicinal Chemistry Nanomedicines as Cancer Therapeutics: Current Status
Current Cancer Drug Targets Use of Mesenchymal Stem Cells in Crohn's Disease and Perianal Fistulas: A Narrative Review
Current Stem Cell Research & Therapy Stairway to Heaven or Hell? Perspectives and Limitations of Chagas Disease Chemotherapy
Current Topics in Medicinal Chemistry